nach oben

Tumor Biology

Erschienen in:

01.10.2011 | Research Article

Intracellular clusterin negatively regulates ovarian chemoresistance: compromised expression sensitizes ovarian cancer cells to paclitaxel

verfasst von: Mohamed Kamel Hassan, Hidemichi Watari, Lane Christenson, Saverio Bettuzzi, Noriaki Sakuragi

Erschienen in: Tumor Biology | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Understanding the molecular events that lead to paclitaxel (TX) resistance is necessary to identify effective means to prevent chemoresistance. Previously, results from our lab revealed that secretory clusterin (CLU) form positively mediates TX response in ovarian cancer cells. Thus, we had interest to study the role of another non-secreted form (intracellular clusterin (i-CLU)) in chemo-response. Here, we provide evidences that i-CLU form localizes mainly in the nucleus and differentially expressed in the TX-responsive KF cells, versus TX-resistant, KF-TX, ovarian cancer cells and negatively regulate cellular chemo-response. I-CLU was cloned, by deleting the secretion-leading signaling peptide from full-length CLU cDNA, and transiently over-expressed in OVK-18 cells. Forced expression of truncated i-CLU was mainly detectable in the nuclei and significantly reduced cellular growth, accumulating cells in G1 phase which finally died through apoptosis. Importantly, compromised expression of i-CLU under an inducible promoter was tolerated and did not induce apoptosis but sensitized ovarian cancer cells to TX. We then demonstrated that this sensitization mechanism was cell cycle independent and relied on i-CLU/Ku70 binding probably due to controlling the free amount of Ku70 available for DNA repair in the nucleus. Results from CLU immunehistochemistry in ovarian tumor tissues verified the retardation of nuclear CLU staining in the recurrent tumor even though their primary counterparts showed nuclear CLU staining. Thus, the controversial data on CLU function in chemo-response/resistance may be explained by a shift in the pattern of CLU expression and intracellular localization as well when tumor acquires chemoresistance.

Nur mit Berechtigung zugänglich

Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel R, et al. Global cancer facts and figures. Atlanta: American Cancer Society; 2007.

Ahmed FY, Wiltshaw E, Ahern P, Nicol B, Shepherd J, Blake P, et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol. 1996;14:2968–75.PubMed

Piver MS, Malfetano J, Baker TR, Hempling RE. Five-year survival for stage IC or stage I grade 3 epithelial ovarian cancer treated with cisplatin-based chemotherapy. Gynecol Oncol. 1992;46:357–60.PubMedCrossRef

Wright JD, Shah M, Mathew L, Burke WM, Culhane J, Goldman N, et al. Fertility preservation in young women with epithelial ovarian cancer. Cancer. 2009;115:4118–26.PubMedCrossRef

Miller M, Ojima I. Chemistry and chemical biology of taxan anticancer agents. Chem Rec. 2001;1:195–211.PubMedCrossRef

Petrylak D. Docetaxel for the treatment of hormone-refractory prostate cancer. Rev Urol. 2003;5:14–21.

Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007;14:195–208.PubMedCrossRef

McGuire WP, Markman M. Primary ovarian cancer chemotherapy: current standards of care. British J Cancer. 2003;89:3–8.CrossRef

Ozols RF, Young RC. Chemotherapy of ovarian cancer. Semin Oncol. 1984;11:251–63.PubMed

10.

McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. Nat Engl J Med. 1996;334:1–6.CrossRef

11.

Selimovic D, Hassan M, Haikel Y, Hengge UR. Taxol-induced mitochondrial stress in melanoma cells is mediated by activation of c-Jun N-terminal kinase (JNK) and p38 pathways via uncoupling protein 2. Cell Signaling. 2008;2:311–22.CrossRef

12.

Richardson A, Kaye S. Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance. Drug Resist Updat. 2005;5:311–21.CrossRef

13.

Bettuzzi S, Hiipakka RA, Gilna P, Liao S. Identification of an androgen-repressed mRNA in rat ventral prostate as coding for sulphated glycoprotein 2 by cDNA cloning and sequence analysis. Biochem J. 1989;257:293–6.PubMed

14.

Aronow B, Lund SD, Brown TL, Harmony JK, Witte DP. Apolipoprotein J expression at fluid-tissue interfaces: potential role in barrier cytoprotection. Proc Natl Acad Sci. 1993;90:725–9.PubMedCrossRef

15.

Fratelli M, Galli G, Minto M, Pasinetti GM. Role of clusterin in cell adhesion during early phases of programmed cell death in P19 embryonic carcinoma cells. Biochim Biophys Acta. 1996;1311:71–761.PubMedCrossRef

16.

Bettuzzi S, Scorcioni F, Astancolle S, Davalli P, Scaltriti M, Corti A. Clusterin (SGP-2) transient over-expression decreases proliferation rate of SV40-immortalized human prostate epithelial cells by slowing down cell cycle progression. Oncogene. 2002;21:4328–34.PubMedCrossRef

17.

Trougakos IP, Gonos ES. Clusterin/apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol. 2002;11:1430–48.CrossRef

18.

O’Sullivan J, Whyte L, Drake J, Tenniswood M. Alterations in the post-translational modification and intracellular trafficking of clusterin in MCF-7 cells during apoptosis. Cell Death Differ. 2003;10:914–27.PubMedCrossRef

19.

Caccamo AE, Scaltriti MA, Caporali A, D’Arca D, Scorcioni F, Candiano G, et al. Nuclear translocation of a clusterin isoform is associated with induction of anoikis in SV40-immortalized human prostate epithelial cells. Ann NY Acad Sci. 2003;1010:514–9.PubMedCrossRef

20.

Trougakos IP, So A, Jansen B, Gleave ME, Gonos ES. Silencing expression of the clusterin/apolipoprotein J gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res. 2004;5:1834–42.CrossRef

21.

Xie D, Lau SH, Sham JS, Wu QL, Fang Y, Liang LZ, et al. Up-regulated expression of cytoplasmic clusterin in human ovarian carcinoma. Cancer. 2005;2:277–83.CrossRef

22.

Scaltriti M, Brausi M, Amorosi A, Castagnetti G, Astancolle S, Corti AA, et al. Clusterin (SGP-2, ApoJ) expression is down-regulated in low- and high-grade human prostate cancer. Int J Cancer. 2004;108:23–30.PubMedCrossRef

23.

Pucci S, Bonanno E, Pichiorri F, Angeloni C, Spagnoli LG. Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene. 2004;13:2298–304.CrossRef

24.

Gleave M, Miyake H. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World J Urol. 2005;1:38–46.CrossRef

25.

Shannan B, Seifert M, Leskov K, Willis J, Boothman D, Tilgen W, et al. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ. 2006;1:12–9.CrossRef

26.

Collard MW, Griswold MD. Biosynthesis and molecular cloning of sulfated glycoprotein 2 secreted by rat Sertoli cells. Biochemistry. 1987;26:3297–303.PubMedCrossRef

27.

Clark AM, Griswold MD. Expression of clusterin/sulfated glycoprotein-2 under conditions of heat stress in rat Sertoli cells and a mouse Sertoli cell line. J Androl. 1997;18:257–63.PubMed

28.

Kirszbaum L, Bozas SE, Walker ID. SP-40, 40, a protein involved in the control of the complement pathway, possesses a unique array of disulfide bridges. FEBS Lett. 1992;297:70–6.PubMedCrossRef

29.

Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA. Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem. 2003;278:11590–600.PubMedCrossRef

30.

Caccamo AE, Scaltriti M, Caporali A, D’Arca D, Scorcioni F, Astancolle S, et al. Cell detachment and apoptosis induction of immortalized human prostate epithelial cells are associated with early accumulation of a 45 kDa nuclear isoform of clusterin. Biochemical J. 2004;382:157–68.CrossRef

31.

Yang CR, Yeh S, Leskov K, Odegaard E, Hsu HL, Chang C, et al. Isolation of Ku70 binding proteins. Nucleic Acids Res. 1999;10:2165–74.CrossRef

32.

Hassan MK. An association between clusterin over-expression and taxol-resistance in ovarian cancer. Hokkaido Igaku Zasshi. 2008;83:335–46.PubMed

33.

Zhu K, Fukasawa IM, Fujinoki M, Furno M, Inaba F, Yamazaki T, et al. Profiling of proteins associated with cisplatin resistance in ovarian cancer cells. Int J Gynecol Cancer. 2005;15:747–54.PubMedCrossRef

34.

Reddy KB, Jin G, Karode MC, Harmony JAK, Howe PH. Transforming growth factor beta (TGF beta)-induced nuclear localization of apolipoprotein J/clusterin in epithelial cells. Biochemistry. 1996;35:6157–63.PubMedCrossRef

35.

Al-Mohanna MA, Al-Khodairy FM, Krezolek Z, Bertilsson PA, Al-Houssein KA, Aboussekhra A. p53 is dispensable for UV-induced cell cycle arrest at late G(1) in mammalian cells. Carcinogenesis. 2001;22:573–8.PubMedCrossRef

36.

Sensibar JA, Sutkowski DM, Raffo A. Prevention of cell death induced by tumornecrosis factor alpha in LNCaP cells by over-expression of sulfated glycoprotein-2 (clusterin). Cancer Res. 1995;55:2431–7.PubMed

37.

Viard I, Wehrli P, Jornot L. Clusterin gene expression mediates resistance to apoptotic cell death induced by heat shock and oxidative stress. J Invest Dermatol. 1999;112:290–6.PubMedCrossRef

38.

Miyake H, Chi KN, Gleave ME. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res. 2000;6:1655–63.PubMed

39.

Miyake H, Nelson C, Rennie PS, Gleave ME. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res. 2000;60:170–6.PubMed

40.

Wu AJ, Park II, Zhaung L, Lee C. Response to a lethal dose of heat shock by a transient up-regulation of clusterin expression followed by down-regulation and apoptosis in prostate and bladder cancer cells. Prostate. 2002;53:277–85.PubMedCrossRef

41.

Redondo M, Villar E, Torres-Munoz J, Tellez T, Morell M, Petito CK. Over-expression of clusterin in human breast carcinoma. Am J Pathol. 2000;157:393–9.PubMedCrossRef

42.

Albert JM, Gonzalez A, Massion PP, Chen H, Olson SJ, Shyr Y, et al. Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:1845–51.PubMedCrossRef

43.

Miyake H, Gleave M, Kamidono S, Hara I. Over-expression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. Urology. 2002;59:150–4.PubMedCrossRef

44.

Scaltriti M, Santamaria A, Paciucci R, Bettuzzi S. Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells. Cancer Res. 2004;64:6174–82.PubMedCrossRef

45.

Caccamo AE, Scaltriti M, Caporali A, D’Arca D, Corti A, Corvetta D, et al. Ca2þ depletion caused nuclear translocation of a 45 kDa death-isoform of clusterin and anoikis induction in prostate cells. Cell Death Differ. 2005;12:101–4.PubMedCrossRef

46.

Pajak B, Orzechowski A. Clusterin. the missing link in the calcium-dependent resistance of cancer cells to apoptogenic stimuli. Postepy Hig Med Dosw. 2006;60:45–51.

47.

Wei L, Xue T, Wang J, Chen B, Lei Y, Huang Y, et al. Roles of clusterin in progression, chemo-resistance and metastasis of human ovarian cancer. Int J Can. 2009;15:791–806.CrossRef

48.

Moretti MR, Marelli MM, Cariboni A. Clusterin isoforms differentially affect growth and motility of prostate cells: possible implications in prostate tumorigenesis. Cancer Res. 2007;67:10325–33.PubMedCrossRef

49.

Al-Mohanna M, Manogaran P, Al-Mukhalafi Z, Al-Hussein K, Aboussekhra A. The tumor suppressor p16INK4a gene is a regulator of apoptosis induced by ultraviolet light and cisplatin. Oncogene. 2004;23:201–12.PubMedCrossRef

50.

Chow Y, Choudhury A. DNA repair protein: endo-exonuclease as a new frontier in cancer therapy. Future Oncol. 2005;2:265–71.CrossRef

51.

Sorenso CM, Eastman A. Influence of cis-diamminedichloroplatinum (II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Cancer Res. 1988;23:6703–7.

52.

Shannan B, Seifert AM, Boothman AD, Tilgen W, Reichrath J. Clusterin and DNA repair: a new function in cancer for a key player in apoptosis and cell cycle control. J Mol Hist. 2006;37:183–8.CrossRef

53.

Kempt M, Sedgwick G, Jeggo A. X-ray sensitive mutants of CHO cells defective in double strand break rejoining. Mutat Res. 1984;13:189–96.

54.

Jeggo A, Caldecott K, Pidsley S, Banks R. Sensitivity of Chinese hamster ovary mutants defective in DNA double strand break repair to topoisomerase II inhibitors. Cancer Res. 1989;49:7057–63.PubMed

55.

Caldecotti K, Banks G, Jeggo P. DNA double-strand break repair pathways and cellular tolerance to inhibitors of topoisomerase II. Cancer Res. 1990;18:5778–83.

56.

Getts RC, Stamato TD. Absence of a Ku-like DNA end binding activity in the xrs double-strand DNA repair-deficient mutant. J Biol Chem. 1994;269:15981–4.PubMed

57.

Taccioli GE, Gottlieb TM, Blunt T, Priestley A, Demengeot J, Mizuta R, et al. Ku80: product of the XRCC5 gene and its role in DNA repair and V(D)J recombination. Science. 1994;5177:1442–5.CrossRef

58.

Gullo AM, Feng G, Teoh G. The biology of Ku and its potential oncogenic role in cancer. Biochimica et Biophysica. 2006;1765:223–34.

59.

Bettuzzi S, Rizzi F. Nuclear CLU (nCLU) and the fate of the cell. Adv Cancer Res. 2009;104:59–88.PubMedCrossRef

60.

Pucci S, Bettuzzi S. The shifting balance between CLU forms during tumor progression. Adv Cancer Res. 2009;104:25–32.PubMedCrossRef

61.

Rizzi F, Coletta M, Bettuzzi S. Clusterin (CLU): from one gene and two transcripts to many proteins. Adv Cancer Res. 2009;104:9–23.PubMedCrossRef

62.

Bettuzi S, Astancolle S, Guidetti G, Moretti M, Tiozzo A, Corti A. Clusterin (SGP-2) gene expression is cell cycle dependent in normal human dermal fibroblasts. FEBS Lett. 1999;448:297–300.CrossRef

Titel: Intracellular clusterin negatively regulates ovarian chemoresistance: compromised expression sensitizes ovarian cancer cells to paclitaxel
verfasst von: Mohamed Kamel Hassan
Hidemichi Watari
Lane Christenson
Saverio Bettuzzi
Noriaki Sakuragi
Publikationsdatum: 01.10.2011
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 5/2011
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-011-0207-0

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Intracellular clusterin negatively regulates ovarian chemoresistance: compromised expression sensitizes ovarian cancer cells to paclitaxel

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2011

Protein kinase Cα suppresses the expression of STC1 in MDA-MB-231 breast cancer cells

Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells

Promoter hypermethylation of RASSF1A, MGMT, and HIC-1 genes in benign and malignant colorectal tumors

Involvement of ERK1/2/NF-κB signal transduction pathway in TF/FVIIa/PAR2-induced proliferation and migration of colon cancer cell SW620

BMP-4 expression has prognostic significance in advanced serous ovarian carcinoma and is affected by cisplatin in OVCAR-3 cells

The nucleosome binding protein NSBP1 is highly expressed in human bladder cancer and promotes the proliferation and invasion of bladder cancer cells

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie